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Abstract
Background Medial vascular calcification is a specific
complication in chronic kidney disease (CKD) patients
although its pathogenesis is poorly understood. The
administration of iron (Fe), generally used for the treatment
of anemia in CKD patients, induces oxidative stress. Fe
loading possibly affects the progress of vascular calcifica-
tion in uremia. We investigated the effect of Fe on vascular
calcification and its mechanism in uremic rats.
Method Thirty-two rats were divided into four groups:
untreated rats (controls), rats fed a standard diet with Fe
administration (Fe group), rats fed an adenine-enriched diet
(uremic group), and rats fed an adenine-enriched diet with
Fe administration (uremic ? Fe group). Iron dextran was
administered once a week for 5 weeks intraperitoneally.
Morphological alterations and vascular calcification-asso-
ciated factors in the aortic wall were evaluated.
Results No aortic calcification was observed in the con-
trol group although uremic rats developed severe vascular
calcification. Fe loading suppressed vascular calcification
in the uremic groups. Expressions of runt-related tran-
scription factor 2 (Runx2), single-strand (ss)DNA and
phosphate transporter (Pit)-1 were increased in the uremic
rats compared to the control rats. In the uremic group, Fe
administration did not show any effect on ssDNA expres-
sion, but reduced Runx2 and Pit-1 expressions.
Conclusion Fe suppressed the development of vascular
calcification through the prevention of Pit-1 and vascular
smooth muscle cell osteoblastic transdifferentiation.
Keywords Iron dextran  Osteoblastic
transdifferentiation  Mo¨nckeberg medial calcification 
Runx2  Pit-1
Introduction
Chronic kidney disease (CKD) is an independent risk factor
for the development of cardiovascular disease (CVD) and
the increased morbidity and mortality associated with CVD
[1]. Medial calcification is a characteristic finding in vas-
cular pathological change in end-stage kidney disease [2].
This pathologic mechanism is caused by a metabolic
abnormality of calcium and phosphate [3]. Previous studies
have revealed that hyperphosphatemia caused by CKD
triggers the mechanism for transformation of vascular
smooth muscle cells (VSMCs) to chondrocytes or osteo-
blast-like cells, and medial-based calcification deposits [4].
Endothelial dysfunction corresponding to a uremic
condition plays an important role in the development of
CVD. Oxidative stress is generally known as one of the
factors affecting endothelial dysfunction and the develop-
ment of atherosclerosis [5]. Iron (Fe) loading increases
oxidative stress and causes endothelial dysfunction. While
ferritin preserves Fe excess, it counteracts the toxicity of Fe
and protects against oxidative stress [6]. However, there
has been no investigation into the effect of Fe adminis-
tration on vascular calcification in the uremic condition
in vivo. The objective of the present study was to evaluate
the effect of Fe on the development of vascular calcifica-
tion and its mechanism in uremic rats.
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Materials and method
Laboratory animals and experimental design
Experiments were performed on 32 Sprague–Dawley male
rats at 10 weeks of age purchased from Charles River
Japan (Kanagawa Prefecture, Japan). The study protocol
was reviewed and approved by the Animal Care and Use
Committee of the Juntendo University Faculty of Medi-
cine. Before the start of this study, the rats were condi-
tioned on a standard diet (CE-2; 1.02 % phosphorus,
1.08 % calcium, 25.1 % crude protein and 2.4 IU/g vita-
min D3) (CLEA Japan, Tokyo, Japan) for 2 weeks. The
rats were housed in cages (two or three animals in each
cage) and allowed free access to food and tap water. The
animal room was kept on a 12 h light/dark cycle
(7:00 a.m. to 7:00 p.m. in the dark, 7:00 p.m. to 7:00 a.m.
in light), at a constant temperature (22 ± 1 C) and rel-
ative humidity of 55 ± 5 % throughout the experimental
period.
After the conditioning period, the 32 rats were divided
into two groups, i.e. normal (standard diet) and adenine
diet. Sixteen rats were fed a 0.75 % adenine-containing
(Sigma Chemical Co., St Louis, MO, USA), phosphate-
enriched diet (1.20 % phosphorus, 1.12 % calcium, 25.1 %
crude protein and 2.4 IU/g vitamin D3) (CLEA Japan,
Tokyo, Japan) to induce uremia for 4 weeks [7]. In the
4 weeks following adenine withdrawal, the rats were fed a
simple phosphate-enriched diet until sacrifice (uremic
group). The other 16 rats were continuously fed the
standard diet for 8 weeks until sacrifice (control group).
The experimental design is summarized in Fig. 1.
Administration of iron dextran (Fe)
We injected 40 mg of Fe (100 g Fe2?/l; Sigma, St Louis,
MO, USA) intraperitoneally on days 14, 21, 28, 35 and 42
into 8 normal diet rats and 8 adenine diet rats. Sterile saline
at 0.4 ml was injected as a control in the other 8 normal diet
rats and other 8 adenine diet rats. Accordingly, the 32 rats
were divided into four groups of eight animals each, as
follows: the control group, the Fe only group, the uremic
group and the uremic ? Fe group. On day 56, all rats were
sacrificed by heart puncture under ether anesthesia according
to the guidelines of the Animal Care and Use Committee of
the Juntendo University Faculty of Medicine.
Body weight and blood pressure
Body weight and blood pressure were measured on days 0,
28 and 56. Systolic arterial blood pressure (SBP) of pre-
warmed rats was measured by the tail-cuff method (BP-
98A; Softron, Tokyo, Japan).
Blood sampling and analysis
Blood samples were obtained on days 0, 28 and 56 in each
group from the tail vein and were also obtained by heart
puncture under ether anesthesia on day 56. Serum creatinine
(Cr), hematocrit (Ht), iron (Fe), transferrin saturation (TS),
Fig. 1 Experimental design.
Body weight and blood pressure
were measured, and blood
samples were taken on days 0,
28 and 56. Closed triangles
indicate administration of
40 mg iron dextran (Fe)
intraperitoneally. Open
triangles indicate administration
of 0.4 ml sterile saline
intraperitoneally. Stars indicate
the times of blood sampling and
measuring blood pressure and
body weight
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ferritin, corrected calcium, phosphorus, intact parathyroid
hormone, 25(OH)D3, 1,25(OH)2D3, fibroblast growth factor
23 (FGF23), alanine aminotransferase (ALT), aspartate ami-
notransferase (AST) and alkaline phosphatase (ALP) were
measured in a commercial laboratory (SRL Co. Tachikawa
City, Japan).TS was calculated from the ratio of serum Fe:
total iron-binding capacity.
Quantitative assessments of vascular calcification
The thoracic aorta was fixed in neutral buffered formalin
and then cut into 2–3 mm thick rings that were embedded
upright in the same paraffin block. Every section comprised
an average of 12 cross-sections of the aorta at different
sites along the vessel. Sections of 4 lm were stained using
the von Kossa method. Vascular calcification was then
evaluated histomorphometrically with image analysis
software, Image-Pro4.5J (Planetron, Tokyo, Japan), at
1009 magnification. Absolute whole vascular walls and
the calcified areas were measured for each animal, and the
calcification ratio was expressed as the percentile of cal-
cification area in vascular wall by the following formula:
Calcification ratio (%) = von kossa - positive area
(lm2)/total vascular wall area (lm2) 9 100.
Immunohistochemistry
Thoracic aorta were fixed in 10 % phosphate-buffered for-
malin and embedded in paraffin. The paraffin-embedded
specimens were sliced into 5-in. sections and stored at room
temperature prior to use. Routine histology (hematoxylin and
eosin staining) was performed in order to evaluate the basic
histomorphological features of the specimens. All sections
were deparaffinized in xylene, followed by 100 % ethanol,
and then placed in a freshly prepared methanol/0.3 % H2O2
solution for 15 min for blocking of endogenous peroxidase
activity. After washing three times with phosphate buffered
saline (PBS), microwave antigen retrieval was performed with
a hot 0.01 mol/l-citrate buffer (pH 6.0) for 20 min. The sec-
tions were allowed to reach room temperature before sub-
sequent procedures were performed. The sections were
incubated with a blocking solution (2 % bovine serum albu-
min, 2 % fetal calf serum, 0.2 % fish gelatin) at room tem-
perature for 30 min after washing three times with PBS. The
sections were then incubated with a monoclonal mouse anti
runt-related transcription factor 2 (Runx2) antiserum, (Ab-
nova Corporation, Taiwan) (1:333) or polyclonal rabbit sin-
gle-strand (ss)-DNA antibody (DAKO, Carpinteria, CA,
USA) (1:2,000) diluted with blocking solution at 4 C over-
night. Negative staining was confirmed by incubation without
primary or secondary antiserum. These sections were incu-
bated with the diluted peroxidase-labeled secondary antise-
rum (DAKO, Carpinteria, CA, USA) at room temperature for
30 min. A 3,30-diaminobenzidine chromogen substrate solu-
tion was applied for 2 min to develop the stain. The sections
were counterstained with hematoxylin, mounted, and then
coverslipped until microscopic analyses. The number of
Runx2 or ss-DNA positive cells in vascular walls was sepa-
rately counted in each specimen (1,400 lm 9 1,000 lm) for
quantitative assessments. The cell density in each area was
calculated as the cell count divided by the total area by
examiners blinded to the treatment regimen.
Quantitative real-time reverse transcriptase-polymerase
chain reaction (PCR) analysis
Total RNA was extracted from the frozen thoracic aorta
using a trizol reagent (Invitrogen AG, Basel, Switzerland)
and the RNeasy Mini Kit (Qiagen K.K., Tokyo, Japan). A
16 ll reaction mixture containing 1 lg of RNA, 4 ll of
2.5 mmol/l dNTP mixture (Takara Biochemicals, Ohtsu
City, Japan) and 2 ll of Random Decamers RETROscript
(Ambion Inc., Austin, TX, USA) in RNase-free water was
inactivated by heating at 70 C for 3 min. The product was
added to 2 ll of a 109 PCR buffer (Takara Bio Inc., Shiga,
Japan), a 1 ll of Protector RNase Inhibitor (Roche Diag-
nostics Corp., Mannheim, Germany) and 0.5 ll of Moloney
murine leukemia virus reverse transcriptase (Invitrogen
Corp., Carlsbad, CA, USA), followed by incubation at 42 C
for 60 min. A 2 ll aliquot of diluted complementary
(c)DNA, 1.6 ll forward primers, 1.6 ll reverse primer,
10 ll SYBR Green PCR Master Mix (Applied Biosystems,
Carlsbad, CA, USA) and 4.8 ll of cDNA-free double-dis-
tilled water were then mixed to obtain a final reaction
mixture of 20 ll according to the manufacturer’s instruc-
tions. The mixture was denatured and amplified using the
7500 Real-Time PCR system (Applied Biosystems) under
the following conditions: (i) 20 s at 95 C for 1 cycle, (ii)
3 s at 95 C and 30 s at 60 C for 40 cycles, (iii) 15 s at
95 C, 60 s at 60 C, 15 s at 95 C and 15 s at 60 C for 1
cycle. cDNA-free double-distilled water as negative control
was included in each reaction. For quantification of the PCR
product, the samples were standardized with a PCR product
for glyceraldehydes-3-phosphate dehydrogenase. The PCR
primers were designed as follows: Runx2, 5-ACAGAA
CCACAAGTGCGGTGCAA-30 (forward),50-TGGTCTC
GGTGGCTGGTAGTGA-30 (reverse) and phosphate trans-
porter (Pit)-1, 50-TACCATCCTCATCTCGGTGG-3 (for-
ward), 50-TGACGGCTTGACTGAACTGG-3 (reverse).
Statistical analysis
All numerical data are expressed as mean ± SD. Differ-
ences between the groups were examined for statistical
significance by analysis of variance. A p value \0.05 was
considered as a statistically significant difference.
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Statistical analyses were performed using Stat View 5.0
software (Abacus Concepts, Inc., Stanford, CA, USA).
Results
Biochemical characteristics and biochemical findings
among the groups
The biochemical characteristics and biochemical findings
of the four groups are shown in Table 1. Adenine feeding
for 4 weeks induced a ten-fold elevation of serum creati-
nine in rats compared to normal diet. Uremic condition
induced by adenine-feeding decreased the levels of
hematocrit. Fe loading did not improve the renal function
and anemia in the uremic ? Fe group. Levels of serum iron
concentration (Fe), transferrin saturation (TS) and serum
ferritin in Fe-treated rats (the Fe alone group and the ure-
mic ? Fe group) were significantly elevated by Fe
administration. Levels of TS and serum ferritin in the
uremic ? Fe group were higher than those in the uremic
group. Uremic condition suppressed vitamin D activation
through an increase of FGF23. Fe administration reversed
this phenomenon without serum phosphate deletion. In the
uremic and uremic ? Fe groups, serum calcium concen-
trations were significantly lower, and serum phosphate
concentrations were higher than those in the control and Fe
only groups. The level of serum phosphate did not differ
between the uremic and the uremic ? Fe groups. Fe
administration slightly increased ALT and AST levels but
did not induce liver injury. Serum ALP was increased in
the uremic and the uremic ? Fe groups.
Vascular medial calcification in the thoracic aorta
No calcified lesions were observed in the control and Fe
only groups (Fig. 2a, b). A calcified band in the thoracic
media was observed in the uremic group (Fig. 2c). Frag-
mented calcification in the thoracic media was observed in
the uremic ? Fe group (Fig. 2d). The areas of calcification
(positive areas in a von Kossa stain) in the uremic rats were
significantly larger than those in the control rats (Fig. 2e).
The increase of the calcified areas in the uremic rats was
remarkably suppressed by Fe administration (Fig. 2F).
Expression of Pit-1 in the thoracic aorta
Pit-1 was not detected in the control and Fe only groups
(Fig. 3a, b). Pit-1 expressing areas were scattered
throughout the whole smooth muscle layer (Fig. 3c–f).
Dotted Pit-1 expressing areas were found in the smooth
muscle layer (Fig. 3e, f). Multi-layered construction in
thoracic media was ruptured around Pit-1 expressing areas
(Fig. 3d–f). Pit-1 mRNA expression, elevated in the uremic
condition, was suppressed by Fe administration (Fig. 3g).
Expressions of ss-DNA and Runx2
Many ss-DNA expressing cells, a specific apoptotic mar-
ker, were present in the uremic groups (Fig. 4a, b).
Table I Characteristics and biochemical parameters in treated groups on day 56
Parameters Control group (n = 8) Control ? Fe group (n = 8) Uremic group (n = 6) Uremic ? Fe group (n = 6)
SBP (mmHg) 121.9 ± 3.7 126.3 ± 10.8 131.7 ± 204 116.1 ± 9.3
BW (g) 534.4 ± 21.9 503.9 ± 20.7 294.5 ± 29.9a 296.8 ± 33.4a,b
Cr (mg/dl) 0.33 ± 0.03 0.34 ± 0.03 3.36 ± 0.74a 2.96 ± 0.84a,b
Ht (%) 53.9 ± 2.4 52.3 ± 3.1 27.9 ± 6.3a 25.7 ± 3.3a,b
Fe (lg/dl) 181.8 ± 36.6 323.1 ± 95.9a 146.0 ± 32.0 291.2 ± 47.8a,b
TS (%) 27.5 ± 6.2 49.2 ± 12.7a 40.2 ± 4.60 82.2 ± 14.1b,c
Ferritin (ng/ml) 2,618.8 ± 496.6 9,883.5 ± 3,757.5a 1,753.3 ± 491.4 15,116.7 ± 6,724.1b,c
Corrected Ca (mg/dl) 11.6 ± 0.37 12.3 ± 0.46 8.73 ± 1.53a 8.97 ± 1.15a,b
Pi (mg/dl) 9.03 ± 0.56 8.95 ± 0.59 17.35 ± 3.06a 15.28 ± 3.54a,b
ALT (mg/dl) 70.5 ± 29.5 138.63 ± 98.1 52.5 ± 24.5 63 67 ± 60.8
AST (mg/dl) 116.6 ± 31.6 204.5 ± 145.7 62.3 ± 11.4a 91.5 ± 66.3a,b
Intact PTH (pg/ml) 6,111.5 ± 1,578.3 425.1 ± 385.2 24,533.3 ± 9,575.7a,b 21,790.0 ± 10,449.0a,b
25(OH)D3 (ng/ml) 32.6 ± 5.15 32.0 ± 9.4 31.8 ± 13.0 33.6 ± 14.7
l,25(OH)2D3 (pg/ml) 133.0 ± 20.1 133.2 ± 27.1 24.0 ± 8.1
a,b 99.8 ± 107.1c
FGF23 (pg/ml) 56.8 ± 12.2 103.1 ± 22.6 74,502.0 ± 10,046.2a,b 2,672 4 ± 3,394.8c
SBP systolic blood pressure, BW body weight Cr serum creatinine, Ht hematocrit, Fe serum iron, TS transferrin saturation, Ca calcium, Pi
inorganic phosphate, ALT alanine aminotransferase, AST aspartate aminotransferase
a p \ 0.05 vs. the control group, b p \ 0.05 vs. the control ? Fe group, c p \ 0.05 vs. the uremic group All data are given as mean ± SD
138 J Nephrol (2014) 27:135–142
123
However, the number of ss-DNA expressing cells in the
Fe-treated group was comparable with that in the uremic
groups (Fig. 4e). Runx2, an osteo-/chondrogenic conver-
sion marker, was abundantly observed in the vessels of the
uremic group. In an immunohistochemical analysis, Runx2
expressing cells were present in the VSMCs (Fig. 4c, d).
Expression of Runx2 was observed in cytoplasmic areas in
the uremic groups (Fig. 4c, d). Administration of iron
dextran (Fe) suppressed increasing Runx2 positive areas
and expression of Runx2 mRNA introduced by uremic
condition (Fig. 4f, g).
Discussion
Our examination revealed the following points: (1) ure-
mic condition induced significant vascular calcification in
the rats fed a phosphorun enriched diet, (2) Fe sup-
pressed the medial vascular calcification induced by the
uremic condition, (3) the suppressive effect of Fe on
vascular calcification could be introduced by the
inhibition of SMCs transforming to osteoblast/chon-
drocyte-like cells.
Fe, a strong inducer of oxidative stress, is commonly
administered to CKD patients with anemia. A previous
study indicated that Fe promotes endothelial injury and
dysfunction, as well as monocyte adhesion in cultured
endothelial cells [8]. However, Fe administration had no
additional effect on these levels in the uremic condition,
although marked Fe accumulation in the liver was observed
at a sufficient dosage (data not shown). According to these
results, the effect of Fe through oxidative stress might be
transient on endothelial cells, or there are unknown factors
or a cross-relationship surrounding endothelial dysfunction
in uremia.
The development of vascular calcification is started by
the uptake of phosphate into SMCs through the excessive
expression of the phosphate transporter Pit-1 [9]. We
confirmed that Fe suppressed the elevated Pit-1 expression
induced by uremic condition regardless of serum phosphate
level alteration. Since the levels of serum FGF23 decreased
in the uremic ? Fe group without a decrease of serum
Fig. 2 Monocyte adhesion to the endothelium and arterial calcifica-
tion. Representative von Kossa staining on day 56 in the control group
(a), the Fe group (b), the uremic group (c), and the uremic ? Fe
group (d). e The area of calcification in the uremic ? Fe group was
significantly suppressed compared to that in the uremic group
(p \ 0.05). ap \ 0.001 versus the control group, bp \ 0.001 versus
the Fe group. Data are expressed as mean ± SD in each group
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phosphate, we suspect that Fe might play a role in the
regulation of FGF23 directly or indirectly. The intracellular
phosphate uptake induces the development of vascular
calcification via two pathways. The first is a matrix vesicle
releasing pathway. The rising concentration of intracellular
phosphate in SMCs makes hydroxyapatite in the matrix
vesicle, and then apoptotic SMCs released in the matrix
vesicle become footholds for interstitial calcification
depositions. A previous study has reported that SMC
apoptosis was induced and accelerated by intracellular
phosphate uptake [10]. A uremic condition induced
accelerating apoptosis in the vascular walls, but no sup-
pressive effect of Fe was observed in our study. An
increase of extracellular phosphate intensifies the expres-
sion of Runx2, which has taken the place of myocardin—
an essential transcription cofactor located at the genetic
locus for SMCs differentiation, and induces the transdif-
ferentiation to osteoblasts [11]. In our study, Fe was able to
Fig. 3 Effect of iron dextran on Pit-1 expression of thoracic aorta.
Phosphate transporter (Pit)-1 was not detected in the control and Fe
only groups (a 1009 magnification, b 4009 magnification). Pit-1
expressing areas were scattered throughout the whole smooth muscle
layer (b 1009 magnification, c 4009 magnification). Pit-1 expressing
areas were found in smooth muscle layer (e 1009 magnification,
f 4009 magnification). Levels of Pit-1 mRNA in each group are
shown g. Data are expressed as mean ± SD in each group
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suppress the SMC transformation into osteoblast-like cells
in the uremic condition.
Ferritin is a Fe storage protein that exhibits antioxidant
properties and is cytoprotective for the endothelium [6].
Ferritin suppressed calcium deposition and osteoblastic
differentiation of VSMCs cultured in a high phosphate
medium [12]. Since the levels of ferritin in the Fe-treated
groups were significantly elevated, especially in the ure-
mic ? Fe rats, ferritin might play a role in the spurring
vascular calcification. It is recognized that Fe may have a
direct effect on osteoblast function and patients with overt
evidence of Fe administration have been shown to have a
mineralization defect on bone biopsy [13]. Fe administra-
tion ameliorated osteoblastic phenotypic change and
function in fetal rat calvaria cultures [14]. This is the first
paper to show directly effects of Fe on VSMCs in vivo.
Originally, we hypothesized that Fe administration may
enhance vascular calcification in the uremic condition.
However, this study has indicated precisely the opposite
results. Recently, a new Fe-based phosphate binder is under
development [15]. Fe deposition was observed in the vas-
cular medial layer of the arteries in this study (data not
shown), which might have a direct physicochemical effect
on vascular calcification. Fe itself may play an important
role in SMCs as a cytotoxic factor. It is important to further
examine the effect of Fe on the endothelial dysfunction
in vivo, and the relationship between the endothelial dys-
function and the vascular calcification.
It appears that Fe administration suppresses excessive
vascular medial calcification in the uremic condition
through the suppression of Pit-1 expression and VSMC
transformation into the osteoblast-like cells.
Fig. 4 Expressions of apoptotic marker (ss-DNA) and osteo-/chon-
drogenic conversion marker (Runx2) in the thoracic aorta. Represen-
tative immunohistochemical findings of ss-DNA and Runx2 in the
uremic rats (a–d). Immunohistochemistry for Runx2 c, d showed a
predominantly cytoplasmic distribution pattern in the uremic group
compared with the uremic ? Fe group. Not Fe but uremic condition
increased the number of ss-DNA positive cells (e). Increased number
of Runx2 positive cells by uremic condition was suppressed by Fe (f).
Levels of Runx2 mRNA in each group are shown (g). Data are
expressed as mean ± SD in each group
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